曲美替尼
医学
达布拉芬尼
肿瘤科
肺癌
内科学
突变
靶向治疗
癌症研究
转移性黑色素瘤
威罗菲尼
MAPK/ERK通路
激酶
癌症
遗传学
基因
生物
作者
Y. Fan,Zhou Jian-ying,Z. Yuanyuan,Y. Yan,Y. Nong,L. Juan,W. Jialei,Z. Jun,Wang Zhe-hai,C. Jun,T. Zhu,Hui Li,Z. Li
标识
DOI:10.1016/j.jtho.2022.07.734
摘要
The prevalence of BRAF V600 mutation in Chinese patients with non-small cell lung cancer (NSCLC) is 1.7%-1.8%; however, no BRAF targeted therapy is currently approved in China. The combination of dabrafenib plus trametinib is approved in the United States, the European Union, Japan and other countries for the treatment of BRAF- mutated NSCLC. The study evaluated the efficacy and safety of dabrafenib plus trametinib in Chinese patients with BRAF V600E- mutated metastatic NSCLC.
科研通智能强力驱动
Strongly Powered by AbleSci AI